Form 4: ResMed CEO Sells Shares Under Pre-Arranged Plan

ResMed Inc. Chairman and CEO Michael J. Farrell sold 4,991 shares of common stock on December 8, 2025, following the exercise of options, under a Rule 10b5-1 plan.

Summary

• Michael J. Farrell, Chairman and CEO of ResMed Inc. (RMD), engaged in an insider transaction on December 8, 2025.
• The transaction involved the exercise of 4,991 stock options at an exercise price of $146.34 per share.
• Concurrently, 4,991 shares of ResMed Common Stock were sold at a weighted average price of $251.4117 per share, with trades ranging from $249.63 to $255.775.
• These transactions were conducted under a pre-arranged Rule 10b5-1 plan, which was adopted on October 31, 2024.
• Following these transactions, Michael J. Farrell directly beneficially owns 466,223 shares of ResMed Common Stock.
• Additionally, 2,090 shares are indirectly beneficially owned through the Lisette and Michael Farrell Family Trust.
• Mr. Farrell also holds 54,903 derivative securities (stock options) with an exercise price of $146.34, which became exercisable starting November 11, 2020, and expire on November 21, 2026.

Sentiment

Score: 6

Explanation: The transaction represents a pre-planned exercise of options and sale of shares by the CEO, resulting in a significant profit for the insider. The pre-scheduled nature under a Rule 10b5-1 plan mitigates any negative market interpretation typically associated with insider selling, making the sentiment neutral to slightly positive due to the profit realized.

Positives

• The CEO realized a significant profit from the exercise of options and subsequent sale of shares, with the sale price substantially higher than the exercise price.
• The transaction was executed under a Rule 10b5-1 plan, indicating it was pre-scheduled and not based on immediate, material non-public information, which enhances transparency.

Negatives

• An insider sale, even if pre-planned, can sometimes be perceived by the market as a lack of confidence, although the 10b5-1 plan mitigates this interpretation.

Future Outlook

N/A

Industry Context

This filing details an individual insider transaction and does not provide broader industry context or trends.

Corporate Governance

Related Party Transactions

• Indirect beneficial ownership of 2,090 shares through the Lisette and Michael Farrell Family Trust is reported.

Stakeholder Impact

• Shareholders might observe the CEO's profitable transaction, but the pre-planned nature under Rule 10b5-1 mitigates concerns about market timing, suggesting minimal direct impact on company valuation or strategy.

Key Dates

Recommendation

The Form 4 filing details a pre-planned insider transaction by the CEO, involving the exercise of options and subsequent sale of shares. While the CEO realized a significant profit, the transaction was executed under a Rule 10b5-1 plan, indicating it was scheduled in advance and not based on new, material non-public information. This type of transaction typically does not signal a change in the company's fundamental outlook or warrant a strong buy or sell recommendation based solely on this filing. Investors should continue to hold and monitor broader company performance and market conditions.

Keywords

ResMed, RMD, Michael J. Farrell, Insider Trading, Form 4, Stock Sale, Options Exercise, CEO, Rule 10b5-1